| News

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration



-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as measured by western blot --

-- Mean NSAD score improvement of 5.7 points from baseline was sustained through 24 months in low-dose cohort, and mean NSAD score improvement of 4.0 points from baseline at one year in high-dose cohort --

-- Results in both cohorts continue to reinforce the safety and tolerability profile of SRP-9003 --


Read More

+39 328 0075986 This email address is being protected from spambots. You need JavaScript enabled to view it.

Via Civasca 112 23018 Talamona - SO  Italia

Made by Betsoft

Sign Up Today!

Sign up to be included in the GFB Lgmd Patient Network where you will receive cutting edge research updates from the leading experts in the world and also be invited to hear about new clinical trials.
Anyone can join the GFB Lgmd Patient Network.
Sign Up